Today, the U.S. Food and Drug Administration (FDA) approved a new recombinant growth hormone manufactured by the Canadian drug company, Cangene, and designed for subcutaneous injection. The brand name for Cangene’s injectable growth hormone is Accretropin. Accretropin has an identical amino acid sequence to natural human growth hormone produced in the pituitary. It was approved for treatment of children with short stature and Turner’s Syndrome (a chromosomal disorder in girls resulting in short stature and infertility). Cangene submitted the new drug application (NDA) to the FDA in July 2006.
 Accretropin joins several other 191-amino acid sequence growth hormone brands currently approved by the FDA including Nutropin AQ, Saizen, Genotropin, Humatrope, Serostim, Zorbtive, Norditropin and Zomacton
About Millard Baker
Millard Baker+ is the founder and editor of MESO-Rx, a website that provides information on the medical and non-medical uses of anabolic-androgenic steroids. He also writes about anabolic steroids and performance enhancing drugs and their use and impact in sport and society.
Web | Twitter | Facebook | More Posts (583)